比利时养老院苯二氮䓬类药物使用与减处方:COME-ON研究结果
该研究为COME-ON集群对照试验的事后分析,纳入比利时54家养老院797名居民,描述苯二氮䓬受体激动剂(BZRA)使用与减处方情况。基线52.4%居民使用BZRA,超过67%的使用者存在超4周使用、联用≥2种其他中枢活性药物或合并谵妄、认知障碍、跌倒或骨折等不适宜指征。28.1%使用者发生减处方,干预组32.9%、对照组22.1%,痴呆和干预分组与减处方相关。
要点
- 养老院居民BZRA使用率高达52.4%,多数存在不适宜使用指征。
- 减处方总体发生率为28.1%,干预组高于对照组(32.9% vs 22.1%)。
- 痴呆居民减处方可能性更高(OR=2.35),干预组亦与减处方相关(OR=1.74)。
核心结论
- 养老院居民BZRA使用非常普遍且不适宜使用指征常见,减处方发生在约四分之一使用者中,结果令人鼓舞。
研究设计与样本
- COME-ON集群对照试验的事后分析,纳入比利时54家养老院797名具有基线和第15个月完整医疗、临床及用药信息的居民。
主要发现
- 基线时418名(52.4%)居民使用BZRA。
- 超过67%的BZRA使用者存在使用超过4周、联用两种或以上其他中枢神经系统活性药物、或合并谵妄、认知障碍、跌倒或骨折等情况。
- 8个居民相关变量和2个处方者相关变量与规律使用BZRA相关。
- 减处方发生于28.1%的BZRA使用者,干预组为32.9%,对照组为22.1%。
- 痴呆(OR=2.35;95%CI=[1.45-3.83])和干预组(OR=1.74;95%CI=1.07-2.87)与减处方相关。
关键数值与推荐
- 采用2019年美国老年医学会Beers标准和STOPP第2版评估BZRA使用被视为潜在不适当处方的理由。
- 减处方定义为完全停药或降低日剂量。
临床怎么用
- 对养老院BZRA使用者应评估不适宜使用指征(如用药时长、药物相互作用、药物-疾病相互作用),并针对非痴呆患者加强减处方干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: To describe the use and deprescribing of benzodiazepine receptor agonists (BZRAs) among nursing home residents (NHRs), to evaluate appropriateness of use and to identify factors associated with BZRA use and deprescribing. DESIGN: Posthoc analysis of the Collaborative Approach to Optimize Medication Use for Older People in Nursing Homes (COME-ON) study, a cluster controlled trial that evaluated the impact of a complex intervention on potentially inappropriate prescriptions (PIPs) in nursing homes (NHs). SETTING: A total of 54 NHs in Belgium. PARTICIPANTS: A total of 797 NHRs included in the study who had complete medical, clinical, and medication information at baseline and at the end of the study (month 15). MEASUREMENTS: Data were recorded by participating healthcare professionals. Reasons why BZRA use was considered as PIPs were assessed using the 2019 American Geriatrics Society Beers Criteria® and the Screening Tool of Older Persons' Prescriptions (STOPP) criteria, version 2. Deprescribing included complete cessation or decreased daily dose. We identified factors at the NHR, prescriber, and NH levels associated with BZRA use and BZRA deprescribing using multivariable binary and multinomial logistic regression, respectively. RESULTS: At baseline, 418 (52.4%) NHRs were taking a BZRA. The use of BZRA for longer than 4 weeks, with two or more other central nervous system active drugs, and in patients with delirium, cognitive impairment, falls, or fractures was found in more than 67% of BZRA users. Eight NHR-related variables and two prescriber-related variables were associated with regular BZRA use. Deprescribing occurred in 28.1% of BZRA users (32.9% in the intervention group and 22.1% in the control group). In addition to four other factors, dementia (odds ratio [OR] = 2.35; 95% confidence interval [CI] = [1.45-3.83]) and intervention group (OR = 1.74; 95% CI = 1.07-2.87) were associated with deprescribing. CONCLUSION: Use of BZRAs was highly prevalent, and reasons to consider it as PIP were frequent. Deprescribing occurred in one-fourth of NHRs, which is encouraging. Future interventions should focus on specific aspects of PIPs (ie, indication, duration, drug-drug and drug-disease interactions) as well as on nondementia patients.
引用
- Evrard P, Henrard S, Foulon V, et al. Benzodiazepine Use and Deprescribing in Belgian Nursing Homes: Results from the COME-ON Study. J Am Geriatr Soc. 2020. PMID: 32786002. doi:10.1111/jgs.16751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。